Estrogens

Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids

Retrieved on: 
Tuesday, July 20, 2021
Drugs, Chemical compounds, Chemistry, Combination drugs, Estrogens, Estranes, Prolactin releasers, GnRH antagonists, Relugolix/estradiol/norethisterone acetate, Uterine fibroid, Relugolix, Estradiol

With this approval, women and doctors finally have a long-term treatment option, which is important for the management of this condition.

Key Points: 
  • With this approval, women and doctors finally have a long-term treatment option, which is important for the management of this condition.
  • Todays approval of RYEQO, the first and only once-daily long-term treatment for women with uterine fibroids in Europe, marks a major milestone in expanding non-invasive treatment options for this common and potentially debilitating disease, said David Marek, Chief Executive Officer of Myovant Sciences, Inc.
  • Through our partnership with Gedeon Richter, we look forward to supporting even more women suffering from uterine fibroids.
  • RYEQO (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Biochem Launches Biochem® TEST: A Natural Testosterone Booster

Retrieved on: 
Wednesday, July 7, 2021
Hormones, Organic compounds, Chemical compounds, Androstanes, Testosterone, Enones, Estrogens, GABAA receptor positive allosteric modulators

NEW YORK, July 7, 2021 /PRNewswire/ -- Biochem , a company founded on the principles of delivering products rooted in Science by Nature, introduces Biochem TEST, a natural testosterone booster.

Key Points: 
  • NEW YORK, July 7, 2021 /PRNewswire/ -- Biochem , a company founded on the principles of delivering products rooted in Science by Nature, introduces Biochem TEST, a natural testosterone booster.
  • Specifically formulated with vitamins, plus natural herbs, TEST helps men feel their best both inside and outside of the bedroom.
  • "Testosterone is a key male sex hormone produced by the human body.
  • Unfortunately, after age 30, most men begin to experience a gradual decline in free testosterone.

Top 3 Myths vs. Facts when it comes to Low Testosterone

Retrieved on: 
Tuesday, June 15, 2021
Hormones, Organ systems, Endocrine system, Testosterone, Estrogens, Androstanes, Enones, GABAA receptor positive allosteric modulators, Hypogonadism, Libido, Masculinizing hormone therapy, Luteoma

It may take several measurements of testosterone in the blood to make a diagnosis since testosterone levels tend to change throughout the day.

Key Points: 
  • It may take several measurements of testosterone in the blood to make a diagnosis since testosterone levels tend to change throughout the day.
  • Fact: Low testosterone can develop at any age for a number of reasons.
  • But having a natural decline does not mean you have low testosterone, which is why it's important to talk to your urologist to determine if your low testosterone level is due to normal aging or something else.
  • Fact: While one of the signs of low testosterone is loss of sex drive, low testosterone can be linked to mood swings, fatigue, low energy and a lack of drive to get up and do things.

Largest Real-World Study of Bioabsorbable Testosterone Pellets in Men and Women Shows Low Complication Rates Over 7 Years and 1.2 Million Implants

Retrieved on: 
Tuesday, June 1, 2021
Technology, Health, General Health, Women, Seniors, MEN, Other Science, Other Technology, Research, Consumer, Science, Organic compounds, Receptor agonists, Medical specialties, Estrogens, Testosterone, Androstanes, Enones, GABAA receptor positive allosteric modulators, Androgen replacement therapy, Masculinizing hormone therapy

Practitioners from multiple clinical specialties reported an overall complication rate of less than 1% in 1,204,012 subcutaneous implants performed over a period of seven years.

Key Points: 
  • Practitioners from multiple clinical specialties reported an overall complication rate of less than 1% in 1,204,012 subcutaneous implants performed over a period of seven years.
  • The use of testosterone therapy in men has been increasing progressively year over year since the 1990s.
  • The study is the largest reported retrospective study to evaluate the continuation and complication rates of testosterone pellet implants.
  • We are dedicated to helping patients live better, longer by changing the way healthcare is practiced on a global level.

Study: Testosterone Pellet Therapy Reduces Breast Cancer Incidence in Women

Retrieved on: 
Tuesday, May 11, 2021
Other Health, Research, General Health, Oncology, Consumer, Clinical trials, Science, Women, Biotechnology, Seniors, Other Science, Health, Steroids, Hormones, Organ systems, Estrogens, Enones, Androstanes, GABAA receptor positive allosteric modulators, Testosterone, Androgen replacement therapy, Breast cancer, Medroxyprogesterone acetate

The results of \xe2\x80\x9cThe Testosterone Therapy and Breast Cancer Incidence Study\xe2\x80\x9d were published in the peer-reviewed \xe2\x80\x9cEuropean Journal of Breast Health.\xe2\x80\x9d\nOf the 2,337 women followed over nine years, only 14 developed invasive breast cancer, a marked reduction when compared to historical controls: Age-matched SEER data would have suggested 48 cases (incidence rate of 144/100,000 vs. 223/100,000), and 71 cases would be expected from the placebo arm of the Women\xe2\x80\x99s Health Initiative.

Key Points: 
  • The results of \xe2\x80\x9cThe Testosterone Therapy and Breast Cancer Incidence Study\xe2\x80\x9d were published in the peer-reviewed \xe2\x80\x9cEuropean Journal of Breast Health.\xe2\x80\x9d\nOf the 2,337 women followed over nine years, only 14 developed invasive breast cancer, a marked reduction when compared to historical controls: Age-matched SEER data would have suggested 48 cases (incidence rate of 144/100,000 vs. 223/100,000), and 71 cases would be expected from the placebo arm of the Women\xe2\x80\x99s Health Initiative.
  • The real-world data was collected from January 2010 through October 2020 and included women treated at least twice with hormone pellets consisting of either testosterone alone (640 patients) or testosterone and estrogen (1,737 patients).
  • Use of the validated Menopause Rating Scale questionnaire has yielded objective evidence that testosterone treatment significantly reduces symptoms in pre- and post-menopausal women.\nThis is the second, and largest, long-term study to demonstrate the relationship of testosterone pellet therapy to invasive breast cancer incidence in women.
  • Testosterone was not studied.\nBoth the Glaser and the Donovitz-Cotten studies looked specifically at subcutaneous testosterone pellets.

Elite HRT Releases New Website With Information on Hormone Replacement Therapy

Retrieved on: 
Wednesday, April 21, 2021
Other Health, Health, Pharmaceutical, Technology, Telecommunications, Clinical medicine, Medicine, Health sciences, Testosterone, Androstanes, Enones, Estrogens, GABAA receptor positive allosteric modulators, Hormone replacement therapy, Androgen replacement therapy, Hormone therapy, HRT

b'The physicians at Elite HRT have collaborated on a new website to serve as a one-stop destination for information regarding Hormone Replacement Therapy.

Key Points: 
  • b'The physicians at Elite HRT have collaborated on a new website to serve as a one-stop destination for information regarding Hormone Replacement Therapy.
  • This stylish web destination contains numerous articles regarding the potential benefits and detractions involved in various HRT treatments like Human Growth Hormone Therapy (HGH), Testosterone Replacement Therapy (TRT), and Nutraceutical Injections.
  • With a thorough commitment to providing transparently sourced information and acknowledging the medical professionals who compiled this information, Elite HRT strives to provide information and consultations of the highest quality.\nElite HRT is a telemedicine firm led by a network of physicians specializing in hormone replacement therapies.
  • Those wanting to learn more and contact Elite HRT can visit https://www.elitehrt.com/ and submit a contact request form with background information today.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210421006035/en/\n'

Sizeable Numbers to Endorse Benefits and Efficacy of Umbrella of Hormone Replacement Therapies underscores Growth in Testosterone Replacement Therapy Market, Valuation Projected to touch US $ 2.2 Bn by 2027, Says TMR

Retrieved on: 
Thursday, April 22, 2021
Steroids, Organ systems, Androstanes, Organic compounds, Testosterone, Enones, Estrogens, GABAA receptor positive allosteric modulators, Androgen replacement therapy, Hypogonadism, Testosterone cypionate, Testosterone enanthate

b'ALBANY, N.Y., April 22, 2021 /PRNewswire/ -- Testosterone replacement therapy is widely used treatment for men with symptomatic hypogonadism.

Key Points: 
  • b'ALBANY, N.Y., April 22, 2021 /PRNewswire/ -- Testosterone replacement therapy is widely used treatment for men with symptomatic hypogonadism.
  • The benefits of testosterone replacement therapy manifest as increased energy and libido level, improved bone density and strength, improved muscle strength, and cardioprotective effects.
  • Thus, the positive results of such therapy has led to a substantial demand for testosterone replacement therapy for men with symptomatic hypogonadism, though there is insufficient data for long-term efficacy and safety of the therapy.\nNonetheless, the beneficial effects of testosterone replacement therapy is rarely disputed instead widely publicized that marks bright prospects for the testosterone replacement therapy market.
  • For example, in the recent past, the U.S. FDA provided approval for a generic testosterone gel to use for testosterone replacement therapy for men with symptomatic hypogonadism.

Sizeable Numbers to Endorse Benefits and Efficacy of Umbrella of Hormone Replacement Therapies underscores Growth in Testosterone Replacement Therapy Market, Valuation Projected to touch US $ 2.2 Bn by 2027, Says TMR

Retrieved on: 
Thursday, April 22, 2021
Steroids, Organ systems, Organic compounds, Androstanes, Testosterone, Enones, Estrogens, GABAA receptor positive allosteric modulators, Androgen replacement therapy, Hypogonadism, Masculinizing hormone therapy, Testosterone cypionate

The benefits of testosterone replacement therapy manifest as increased energy and libido level, improved bone density and strength, improved muscle strength, and cardioprotective effects.

Key Points: 
  • The benefits of testosterone replacement therapy manifest as increased energy and libido level, improved bone density and strength, improved muscle strength, and cardioprotective effects.
  • When testosterone is replaced, a number of positive effects of higher testosterone levels are experienced.
  • Thus, the positive results of such therapy has led to a substantial demand for testosterone replacement therapy for men with symptomatic hypogonadism, though there is insufficient data for long-term efficacy and safety of the therapy.\nNonetheless, the beneficial effects of testosterone replacement therapy is rarely disputed instead widely publicized that marks bright prospects for the testosterone replacement therapy market.
  • For example, in the recent past, the U.S. FDA provided approval for a generic testosterone gel to use for testosterone replacement therapy for men with symptomatic hypogonadism.

Lauren Streicher, OBGYN and Menopause Expert, Releases “Slip Sliding Away,” a Guide to Tackling Menopause Symptoms

Retrieved on: 
Tuesday, April 20, 2021
Other Consumer, Women, Cosmetics, Other Health, Seniors, Retail, Parenting, MEN, Baby, Maternity, Family, Consumer, Entertainment, LGBTQ+, General Health, Alternative medicine, Other Retail, Health, Books, Branches of biology, Human reproduction, Anatomy, Human female reproductive system, Mammal female reproductive system, Estrogens, Menopause, Gynaecology, Vagina, Hot flash, Vulva

Yet, 80% of menopausal women experience symptoms such as hot flashes, vaginal dryness, weight gain, hair loss, brain fog, and insomnia, that impede their ability to think, sleep, work, and function sexually.

Key Points: 
  • Yet, 80% of menopausal women experience symptoms such as hot flashes, vaginal dryness, weight gain, hair loss, brain fog, and insomnia, that impede their ability to think, sleep, work, and function sexually.
  • These women are turning to doctors for answers to combat their symptoms, but all too often are not offered solutions.\nEnter Slip Sliding Away: Turning Back the Clock on Your Vagina \xe2\x80\x93 gynecologist and best-selling author Lauren Streicher\xe2\x80\x99s latest resource that every woman needs.
  • This solution-driven guide addresses hormonal and non-hormonal options to alleviate vulvar, vaginal, and urinary symptoms as a result from a lack of estrogen that affects 60-70% of women over the age of 50.
  • Find more information about her practice and books on her website: https://www.drstreicher.com .\nSlip Sliding Away is now available for digital pre-sale; paperback and audio options will be available soon.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210420005233/en/\n'

HealthPoint Plus and Trūman Rx establish strategic partnership

Retrieved on: 
Thursday, April 15, 2021
Organ systems, Organic compounds, Chemical compounds, Androstanes, Testosterone, Enones, Estrogens, GABAA receptor positive allosteric modulators, Telehealth, Healthpoint, Androgen replacement therapy, Harry S. Truman

b'DENVER, April 14, 2021 /PRNewswire/ -- National telehealth provider HealthPoint Plus, an innovative leader in subscription-based telehealth, formed a strategic partnership with the disruptive telehealth testosterone replacement therapy startup Truman Rx (Truman).

Key Points: 
  • b'DENVER, April 14, 2021 /PRNewswire/ -- National telehealth provider HealthPoint Plus, an innovative leader in subscription-based telehealth, formed a strategic partnership with the disruptive telehealth testosterone replacement therapy startup Truman Rx (Truman).
  • The partnership expands the reach of Truman while increasing the services available through HealthPoint Plus.\nTruman founder and CEO, David Hall, said of the partnership, "This is a big win for both companies and men who are needlessly suffering the consequences of low testosterone.
  • Our partnership with HealthPoint Plus allows us to expand our reach across the U.S. and enables us to continue honing our focus on creating a better experience for men who want access to high-quality testosterone therapy.
  • "\nWith COVID-19 reshaping how healthcare is provided, HealthPoint Plus CEO Bob Goddard sees it as imperative to increase the services that are available.